Header Logo

Connection

Richard Pietras to Humans

Back to Details
This is a "connection" page, showing publications Richard Pietras has written about Humans.
Richard Pietras
Connection Strength
1.610
Humans
  1. Manuka Honey Inhibits Human Breast Cancer Progression in Preclinical Models. Nutrients. 2024 Jul 22; 16(14).
    View in: PubMed
    Score: 0.105
  2. Estradiol Induces Neutrophil Expansion to Promote TSC-Null Tumor Progression. Endocrinology. 2023 06 26; 164(8).
    View in: PubMed
    Score: 0.097
  3. Progesterone Receptor Signaling in the Breast Tumor Microenvironment. Adv Exp Med Biol. 2021; 1329:443-474.
    View in: PubMed
    Score: 0.082
  4. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy. J Steroid Biochem Mol Biol. 2019 10; 193:105415.
    View in: PubMed
    Score: 0.073
  5. Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression. Cancer Lett. 2019 05 01; 449:66-75.
    View in: PubMed
    Score: 0.072
  6. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer. 2018 09; 123:91-98.
    View in: PubMed
    Score: 0.069
  7. Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer. Mol Cell Endocrinol. 2018 05 05; 466:51-72.
    View in: PubMed
    Score: 0.066
  8. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci. 2017 Nov 02; 18(11).
    View in: PubMed
    Score: 0.066
  9. Biologic roles of estrogen receptor-ß and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int. 2015; 2015:925703.
    View in: PubMed
    Score: 0.055
  10. Estrogen Receptor-ß and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Crit Rev Oncog. 2015; 20(5-6):373-90.
    View in: PubMed
    Score: 0.054
  11. Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids. 2011 Aug; 76(9):910-20.
    View in: PubMed
    Score: 0.042
  12. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann N Y Acad Sci. 2009 Feb; 1155:194-205.
    View in: PubMed
    Score: 0.036
  13. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer. 2008 Nov 01; 113(9):2385-97.
    View in: PubMed
    Score: 0.035
  14. Estrogen-signaling pathways in lung cancer. Adv Exp Med Biol. 2008; 617:281-9.
    View in: PubMed
    Score: 0.033
  15. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res. 2007 Aug 15; 13(16):4672-6.
    View in: PubMed
    Score: 0.032
  16. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat. 2008 Apr; 108(3):351-61.
    View in: PubMed
    Score: 0.032
  17. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids. 2007 Feb; 72(2):135-43.
    View in: PubMed
    Score: 0.031
  18. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer. Oncologist. 2006 Jul-Aug; 11(7):704-17.
    View in: PubMed
    Score: 0.030
  19. Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol. 2006 Feb 26; 246(1-2):91-100.
    View in: PubMed
    Score: 0.029
  20. Aromatase inhibitors in human lung cancer therapy. Cancer Res. 2005 Dec 15; 65(24):11287-91.
    View in: PubMed
    Score: 0.029
  21. Estrogen receptors and cell signaling. Science. 2005 Oct 07; 310(5745):51-3; author reply 51-3.
    View in: PubMed
    Score: 0.028
  22. New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resist Updat. 2005 Aug; 8(4):219-33.
    View in: PubMed
    Score: 0.028
  23. Overview of the FASEB 2004 summer research conference on steroid hormone receptors: integration of plasma membrane and nuclear-initiated signaling in hormone action. Steroids. 2005 May-Jun; 70(5-7):345-6.
    View in: PubMed
    Score: 0.027
  24. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids. 2005 May-Jun; 70(5-7):372-81.
    View in: PubMed
    Score: 0.027
  25. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat. 2005; 93 Suppl 1:S11-8.
    View in: PubMed
    Score: 0.027
  26. Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J. 2003 Sep-Oct; 9(5):361-73.
    View in: PubMed
    Score: 0.025
  27. Sex steroid hormones and DNA repair regulation: Implications on cancer treatment responses. J Steroid Biochem Mol Biol. 2023 03; 227:106230.
    View in: PubMed
    Score: 0.023
  28. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene. 2002 Apr 25; 21(18):2805-14.
    View in: PubMed
    Score: 0.022
  29. Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine. 2001 Nov; 16(2):73-81.
    View in: PubMed
    Score: 0.022
  30. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene. 2001 Sep 06; 20(39):5420-30.
    View in: PubMed
    Score: 0.021
  31. Steroid hormone receptors in target cell membranes. Endocrine. 2001 Apr; 14(3):417-27.
    View in: PubMed
    Score: 0.021
  32. Cell membrane estrogen receptors resurface. Nat Med. 1999 Dec; 5(12):1330.
    View in: PubMed
    Score: 0.019
  33. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999 Mar 15; 59(6):1347-55.
    View in: PubMed
    Score: 0.018
  34. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene. 1998 Oct 29; 17(17):2235-49.
    View in: PubMed
    Score: 0.018
  35. CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer. Oncotarget. 2017 Jun 13; 8(24):38294-38308.
    View in: PubMed
    Score: 0.016
  36. A83-01 inhibits TGF-ß-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2017 Jun; 163(3):449-460.
    View in: PubMed
    Score: 0.016
  37. Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report. J Med Case Rep. 2016 Dec 03; 10(1):346.
    View in: PubMed
    Score: 0.015
  38. Progesterone receptor (PR) polyproline domain (PPD) mediates inhibition of epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer cells. Cancer Lett. 2016 May 01; 374(2):279-91.
    View in: PubMed
    Score: 0.015
  39. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995 Jun 15; 10(12):2435-46.
    View in: PubMed
    Score: 0.014
  40. Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status. PLoS One. 2015; 10(5):e0127600.
    View in: PubMed
    Score: 0.014
  41. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994 Jul; 9(7):1829-38.
    View in: PubMed
    Score: 0.013
  42. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):270-8.
    View in: PubMed
    Score: 0.012
  43. Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. Lung Cancer. 2011 Nov; 74(2):318-25.
    View in: PubMed
    Score: 0.010
  44. Cathepsin D in breast cancer. N Engl J Med. 1990 Jun 07; 322(23):1673-4.
    View in: PubMed
    Score: 0.010
  45. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res. 2007 Nov 01; 67(21):10484-90.
    View in: PubMed
    Score: 0.008
  46. The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis. 2006 Dec; 27(12):2424-33.
    View in: PubMed
    Score: 0.007
  47. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006 Jan-Feb; 8(1):36-42.
    View in: PubMed
    Score: 0.007
  48. Targeted therapy: wave of the future. J Clin Oncol. 2005 Mar 10; 23(8):1776-81.
    View in: PubMed
    Score: 0.007
  49. Rapid nitric oxide-mediated S-nitrosylation of estrogen receptor: regulation of estrogen-dependent gene transcription. Proc Natl Acad Sci U S A. 2005 Feb 15; 102(7):2632-6.
    View in: PubMed
    Score: 0.007
  50. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004 May 19; 96(10):739-49.
    View in: PubMed
    Score: 0.006
  51. Lysosomal functions in cellular activation: propagation of the actions of hormones and other effectors. Int Rev Cytol. 1984; 88:1-302.
    View in: PubMed
    Score: 0.006
  52. Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem. 2003 Feb 15; 88(3):438-45.
    View in: PubMed
    Score: 0.006
  53. Lysosomal cathepsin B-like activity: mobilization in prereplicative and neoplastic epithelial cells. J Histochem Cytochem. 1981 Mar; 29(3A Suppl):440-50.
    View in: PubMed
    Score: 0.005
  54. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene. 1999 Oct 28; 18(44):6050-62.
    View in: PubMed
    Score: 0.005
  55. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999 Apr 01; 18(13):2241-51.
    View in: PubMed
    Score: 0.005
  56. Elevated serum cathepsin B1-like activity in women with neoplastic disease. Gynecol Oncol. 1979 Feb; 7(1):1-17.
    View in: PubMed
    Score: 0.004
  57. Elevated serum cathepsin B1 and vaginal pathology after prenatal DES exposure. Obstet Gynecol. 1978 Sep; 52(3):321-7.
    View in: PubMed
    Score: 0.004
  58. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. 1997 Jul 31; 15(5):537-47.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.